Review Article

Protein-Mediated Interactions of Pancreatic Islet Cells

Paolo Meda

Department of Cell Physiology and Metabolism, University of Geneva School of Medicine, 1 rue Michel-Servet, 1211 Geneva 4, Switzerland

Correspondence should be addressed to Paolo Meda; paolo.meda@unige.ch

Received 19 November 2012; Accepted 10 December 2012

Academic Editors: B. R. Gauthier, A. Pileggi, and D. Sakamuro

Copyright © 2013 Paolo Meda. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The islets of Langerhans collectively form the endocrine pancreas, the organ that is solely responsible for insulin secretion in mammals, and which plays a prominent role in the control of circulating glucose and metabolism. Normal function of these islets implies the coordination of different types of endocrine cells, noticeably of the beta cells which produce insulin. Given that an appropriate secretion of this hormone is vital to the organism, a number of mechanisms have been selected during evolution, which now converge to coordinate beta cell functions. Among these, several mechanisms depend on different families of integral membrane proteins, which ensure direct (cadherins, N-CAM, occludin, and claudins) and paracrine communications (pannexins) between beta cells, and between these cells and the other islet cell types. Also, other proteins (integrins) provide communication of the different islet cell types with the materials that form the islet basal laminae and extracellular matrix. Here, we review what is known about these proteins and their signaling in pancreatic β-cells, with particular emphasis on the signaling provided by Cx36, given that this is the integral membrane protein involved in cell-to-cell communication, which has so far been mostly investigated for effects on beta cell functions.

1. Introduction

In vertebrates, pancreatic beta cells are the sole source of the insulin hormone [1]. The modulation of insulin secretion as a function of the changing metabolic demand and environmental conditions, specifically the levels of circulating glucose, cannot be quantitatively fulfilled by a single beta cell. Indeed, the total amount of insulin of one cell (∼10 pg) will not allow for establishment and maintenance of the basal circulating levels of the hormone (∼1.25 mg/L in humans). Assuming that all beta cells of the million islets which are thought to be dispersed in a human pancreas contribute to these levels, this implies that about 125 cells should simultaneously secrete in each islet. After a meal, this number should increase by about 5 to 6-fold to rapidly establish the postprandial levels of insulin, which are required to maintain normoglycemia, and be tightly regulated to ensure the peripheral oscillations of the circulating levels of the hormone, which prevent the target tissues to establish a resistance to the hormone [2–4]. Eventually, the mechanism(s) controlling these surge and oscillations should also be able to synchronously turn off the secreting cells, in order to avoid dangerous hypoglycemia, once insulin has launched its anabolic effects. Thus, insulin secretion is a multicellular process, which implies the coordinated functioning of many pancreatic islets, and many beta cells within each of these functional subunits of the endocrine pancreas.

With evolution, many mechanisms have converged to ensure this coordination, which ensures a proper secretion of insulin [5–9]. These mechanisms include several forms of indirect cell-to-cell communication, which use extracellular molecules that simultaneously signal multiple cells, including those mediated by short- and long-range actions of multiple neurotransmitters and hormones, as well as the mechanisms that affect beta cells by several other regulatory ions and low molecular weight second messengers, purinergic signals, and short lived gases. Given that islets are separated from each other by the exocrine acini, as well as by the connective and vascular tissues of pancreas, this set of mechanisms, and notably that mediated by neurotransmitters, is believed not to be dispensable for the islet-to-islet synchronization. This set of mechanisms also controls the function of beta cells within each islet, ensuring a fine tuning of the rapidity, amplitude, rhythmicity, decrease, and duration of the insulin release. This is indicated by the experimental perturbation of these parameters in vitro, that is, under conditions which
alter, if they do not abolish, the intercellular flux of signaling molecules and, hence, the indirect mechanisms of indirect cell-to-cell communication. The regulatory molecules are presumably generated within each islet, inasmuch as isolated islets of Langerhans retain in vitro a close to normal ability to modulate insulin secretion and biosynthesis in response to glucose.

Remarkably, however, the same in vitro conditions do not abolish a major physiological feature of pancreatic beta cells, which is observed in no other vertebrate cell types, that is, their ability to exquisitely sense minute changes in the levels of circulating glucose, and to regulate accordingly the level of insulin secretion. In contrast, this cell-specific feature is rapidly lost once beta cells loose the contacts which they natively establish with each other, and other types of endocrine cells, within the pancreatic islets. Since a partial recovery of this loss is acutely observed after cell reaggregation [5–9], at least some of the many surface proteins which become functionally activated upon beta cell contact appear obligatory for proper insulin secretion.

Like all other types of epithelial cells, beta cells closely adhere to their neighbors by a variety of cell surface proteins [5–9], many of which are members of multigene families. These proteins selectively interact within restricted domains of the cell membrane to form intercellular junctions, or form channels permeable to a variety of ions, metabolites, and second messengers. Some junctions establish adhesive links between adjacent cells, ensuring the structural cohesiveness of the islet, and contribute to the functional polarity of secretory cells, by establishing distinct membrane domains. Other junctions provide for anchoring of the endocrine cells to extracellular pancreas components, which presumably allows for the establishment of pathways that transduce signals within and between cells, in order to couple extracellular changes with intracellular responses. Some channels establish direct exchanges of cytosolic components between adjacent cells, which allows for the synchronization of companion beta cells. Other channels may mediate the coordination of the beta cells with the surrounding alpha cells, which produce glucagon antagonistically with insulin secretion, as well as with the other types of islet cells, including the delta cells, which produce somatostatin in parallel with insulin secretion, the PP cells, which produce pancreatic polypeptide, and the epsilon cells, which produce ghrelin. Together, this set of mechanisms of direct communication ensures the integration of these different cell types within structurally and functionally coherent pancreatic islets [5–9]. Typically, these mechanisms operate over a small distance range, due to their dependence on cell-cell or cell-extracellular material contact, and because they are often diffusion driven, thereby providing a potential clue as to the intriguing small size of pancreatic islets, which has been consistently selected in most animal species [10].

This paper reviews the proteins involved in these direct cell communications [8, 9], and the mechanisms whereby they ensure direct islet cell adhesion (cadherins and Ca\(^{2+}\)-independent junctional molecules), anchoring to the extracellular matrix (integrins), polarity (claudins and occludin), and possibly communications between beta cells and other islet cell types. Specific attention is given to Cx36, the sole connexin expressed by pancreatic beta cells, since increasing evidence points to a relevant in vivo role of the coupling that this protein ensures within the islets, in multiple aspects of beta cell functions.

2. Why Cell-to-Cell Interactions?

A first multi-cellular organism is believed to have formed between cyanobacteria some 3.5 billion years ago, relatively soon after the earth crust solidified [11]. Since, this event repeated itself a number of times [12–20] till about 800 million years ago, when it initiated the development of the larger algae, fungi, plants, and animals we now know [13–16, 21, 22]. This development was accompanied by increased genomic diversity, presumably as a result of the recruitment by multicellular organisms of genes from several unicellular ancestors [18, 19]. This recruitment, together with a series of spontaneous genetic mutations and environmental changes, is the likely cause of the increased size of the newly formed multicellular organism [12, 17]. In turn, this change lead to cell diversity, due to the necessity to sustain the larger body with novel metabolic and structural adaptations [21]. Thus, multiple cell types emerged [16, 21], imposing to the multicellular organism to transform from a mere aggregate of independent cells into a community of interacting cells. The new organisms presumably were selectively advantaged by these changes, since phylogeny shows a trend towards increased organism complexity [18, 19]. In turn, multicellularity provided control over the environment. This facilitated the independent determination of the intracellular medium and the constitution of a stable milieu interieur, which protected the multicellular organisms from environmental alterations [16].

3. How Cell-to-Cell Interactions?

This phenomenal and explosive evolution dependeds on the parallel development of a communication array for cross-talk between the various types of cells that strived to live together. Via such an array, adjacent and distant cells were forced to coordinate their function with that of other cells, to optimize their adaptation to the environment [23, 24]. Likely, this signaling array was initiated by the diffusion across the cell membrane of small signaling molecules [12, 25–32]. Since, selection has largely diversified this primordial mechanism, resulting in a complex array of cross-talking and to some extent overlapping cell communication mechanisms, which use different structures and signal molecules [8, 9]. These mechanisms are referred to as “indirect” or “direct” cell-to-cell communication mechanisms. Indirect cell communication does not require cell contact, being mediated by the extracellular flux of molecules that simultaneously signal multiple cells. A widespread modality of such a mechanism, is the diffusion in the extracellular spaces of hormones and neurotransmitters, which are simultaneously sensed by cells equipped with cognate receptors [28, 29, 31, 32]. This
system ensures a highly specific signaling between both distant (hormonal and neural communication) and nearby cells (paracrine communication), sometimes even affecting the very same cell that generated the signal (autocrine feedback loop). Another widespread form of indirect cell-to-cell communication is provided by the diffusion in the extracellular spaces of ions and molecules that enter cells either by free diffusion through the lipid membrane bilayers or by way of specific transporters/channels [33, 34]. A recently recognized variant of this modality is the release through membrane pannexin channels of cytosolic signal molecules which enter the extracellular fluid and then interact with specific receptors in close-by cells. Cell-to-cell coordination is then achieved by the simultaneous up- or downmodulation of specific metabolic and effectors pathways in several cells. A further modality of “indirect” cell-to-cell communication is the dispersion of the extracellular cell-to-cell signal by components of the extracellular matrix, to which multiple cells may simultaneously and dynamically attach by way of specific integrin proteins, that mediate both in-out and out-in signaling [8, 9].

Possibly because multicellularity initially developed in large aqueous media, most cell types also developed ways to communicate in a “direct” way, that is, by mechanisms which require their physical contact at the level of the cell membrane [8, 9]. A widespread modality of such direct cell-to-cell communications is via a large variety of cell adhesion glycoproteins, referred to as cell adhesion molecules (CAMs), which establish and maintain cell cohesion, while transmitting both intra- and extracellular information to adjacent cells [8, 9]. Direct cell-to-cell communication is also mediated by connexins [35–39], the nonglycosylated proteins that oligomerize to form hydrophilic cell-to-cell channel, which functionally joins two cytoplasm, thus allowing for bidirectional exchanges of a variety of cytosolic molecules [35–39].

Probably because most of these indirect and direct cell communication mechanisms operate in a relatively short distance range, they were not, alone, sufficient to cope with the increasing size and complexification of multicellular systems, which progressively included increasing numbers of cells, differentiating in multiple directions [15, 39]. Thus, the nervous and endocrine systems emerged to carry the signal molecules to both close-by and distant target cells [12, 26, 27, 40, 41]. The use of similar signal molecules and signal molecule-receptor interactions all along the phylogenetic tree suggests that the two systems evolved from a common ancestor [28–32, 40, 42–46], presumably by random modification of some common metabolite [27, 47]. Since, comparative biology has shown little evolutionary changes in the type of hormones produced by different organisms [27, 40, 42], but a large diversification of the types of cells targeted by the signaling molecules, and, to a lesser extent, of the pathways which are controlled by hormones and neurotransmitters in these cells [27, 40, 48]. As a result, a same signaling molecule may have markedly different effects in different species [27]. With the advent of large size vertebrates, the requirement for hormones increased, forcing the development of multicellular glands, where many cells would concentrate to produce one or several signaling molecules. Again, there has been but a modest phylogenetic adaptation of these glands, even when their spatial architecture changed, indicating some need for convergent evolution [25, 27, 49, 50].

4. Hormone Secretion Is a Multicellular Event

The phylogeny of endocrine glands recapitulates several steps of the evolution of multicellularity, notably the essential need for intercellular communication to ensure a coordinated function of the endocrine secretory cells that are vital for mammal survival. Thus, secretion of vital hormones is a multicellular process, given that no individual cell can produce, at any given time, the large amount of hormones that is required to ensure their vascular transport across a large organism, and to regulate the peripheral target organs. Hence, endocrine cells making a specific hormone should synchronize their activity with companion cells, and coordinate this activity with that of cells producing agonistic or antagonistic hormones, which may not function synchronously and at the same rate [51–55]. Since most hormonal secretions undergo regular fluctuations, as a function of circadian and other rhythms, and are affected by changes of the milieu interieur, the extracellular milieu of the organism and the environment, this coordination should be continuously adapted, on a moment-to-moment scale, to provide a hormone output commensurate with the needs of the organism.

Endocrines meet these requirements, by using in parallel, though not necessarily simultaneously, all the indirect and direct forms of cell-to-cell communication mentioned above [51–53, 55–57], in patterns which differ from gland to gland. This organization results in a complex network of different regulatory systems, which largely overlap and, at times, interact with other pathways to promote or decrease their influence. Most likely, this partial redundancy was pressure-selected by the vital necessity of some of the hormones, like insulin or corticosteroids. Providing the cells making these hormones with many regulatory systems ensures that the biosynthesis, storage, and release of these molecules are maintained within a life sustainable range under most conditions, including when individual regulatory mechanism may have been lost. Distinct communication mechanisms, each resulting in quantitatively and qualitatively different effects, also provide endocrine cells with a much more sensitive and graded way to control their functioning, in both temporal and spatial terms, than possible using a single, on/off type of regulation.

5. Cell Interactions in the Endocrine Pancreas

5.1. What Is the Endocrine Pancreas? In mammals, the endocrine pancreas is collectively made by a multitude of islets of Langerhans which are dispersed within the pancreas. Each islet is a round/ovoid mass, 50–600 µm in diameter, which comprises ∼50–3000 cells, of which beta cells represent about 60% in humans. The remaining cells are glucagon-producing alpha cells, somatostatin-producing delta cells, pancreatic polypeptide-producing cells,
and ghrelin-producing epsilon cells. The islets also comprise abundant endothelial cells, as well as some fibroblasts, lymphocytes, and macrophages [58]. This complex organization, and the vital necessity of these microorgans contrast with their actual minute amounts. In humans, the estimated number of pancreatic islets is one million per pancreas, under healthy, control conditions, which means that our survival is dependent on about one billion beta cells. Still, these cells altogether only form 1-2% of the volume of a control, adult human pancreas, and represents no more than 1 g wet weight tissue [58].

5.2. Interactions between Pancreatic Islets. Under resting conditions, the three main islet hormones, insulin, somatostatin and glucagon, are all released in an oscillatory manner [2–4, 59–62], which is synchronous for the two former hormones and antisynchronous for the latter [63]. After a meal, the release of insulin and somatostatin increases sharply, whereas that of glucagon decreases. Conversely, during fasting, insulin and somatostatin are downregulated, whereas the release of glucagon is increased. This regulation implies a coordination between both multiple islets, and between their different cell types, since a stochastic function of individual islets is unlikely to ensure both the acute and important post-prandial surges in the hormone levels, their regular, cyclic fluctuations over time, and their rapid off response when the nutrient stimulation ceases. Given that islets are separated from each other by basal laminae, connective tissue, and the acini of the exocrine pancreas, their coordination depends on a variety of hormonal and neural controls. Thus, insulin secretion is experimentally stimulated by gastric inhibitory peptide, thyrotropin-releasing hormone, glucagon-like peptide 1, β-adrenergic agonists, acetylcholine, cholecystokinin, gastrin-releasing peptide, and vasoactive intestinal peptide [64–67]. Conversely, inhibition is induced by corticotrophin-releasing factor, peptide YY, atrial natriuretic peptide, pancreaticastatin, α2-adrenergic agonists, galanin, neuropeptide 1, and somatostatin [64–67]. In vivo, the insulin secretion of islets, which is initiated by circulating nutrients, mostly glucose, is essentially modulated by gut hormones, specifically gastric inhibitory peptide, glucagon-like peptide 1, cholecystokinin, and somatostatin [64–67]. In vitro, pulsatility of insulin secretion is preserved in the absence of hormonal circulation [2, 3, 66–68], further indicating that some intrapancreatic nervous system helps coordinating the individual islets. Since insulin pulses are altered by tetrodotoxin, but not by drugs blocking cholinergic and adrenergic receptors, this islet coordination presumably involves connections between islets, mediated by postganglionic fibers of autonomous ganglia [64]. These ganglia, which serve both as pancreatic pacemakers and as integration centers [66], receive adrenergic, cholinergic, and peptidergic inputs from both the central and the autonomous nervous systems [66].

5.3. Interactions within Pancreatic Islets. Within each pancreatic islet, endocrine and vascular cells communicate in a variety of ways which presumably include all the indirect and direct mechanisms listed above. Thus, it has long been known that the insulin-producing beta cells regulate their functions through interactions with the same hormones, neuromediators, and other signal discussed in the previous paragraph for islet communication. These signal molecules reach the pancreas from outside or are generated within the islet itself [6, 57, 64, 69, 70]. However, given that insulin secretion is still a regulated event under in vitro conditions which abolish the native blood supply and perturb both the innervation and the flux of extracellular fluid, other communication mechanisms must contribute to beta cell control. The finding that insulin secretion is altered after dispersion of islet cells and rapidly improves after their reaggregation or their interaction with components of the extracellular matrix [71–78], further suggests that these mechanisms depend on the establishment and maintenance of proper cell-to-cell and cell-to-matrix contacts.

5.3.1. Indirect Interactions

Neurotransmitter and Hormone Mediated. Individual islets of Langerhans respond to most of the neuromediators and hormones which affect the endocrine secretion of the intact pancreas, including the four main islet hormones [69, 70, 79]. Thus, insulin inhibits glucagon secretion, and possibly also the secretion of somatostatin, pancreatic polypeptide, and insulin itself; glucagon stimulates insulin and somatostatin secretion; pancreatic polypeptide inhibits somatostatin secretion; and somatostatin inhibits the release of all islet hormones [69, 70, 79]. Some of these effects can be prevented by antibodies to specific hormones, suggesting that they may well be elicited in vivo after release of endogenous islet products [69, 70, 79]. Since islet cells are influenced by hormone levels much lower than those found in the venous effluent of the pancreas, it is difficult to conceive that any paracrine effect may occur by diffusion of hormones from the producing cell to nearby targets, through a continuous extracellular space. If this was the case, it is likely that the islet cell receptors may be downregulated by the sustained exposure to high hormone concentrations [69, 70, 79]. Thus, it is likely that islet hormones are channeled to specific membrane domains, either by restricted diffusion in the extracellular islet space or by vectorial transport via the islet microcirculation [64, 66, 69, 70, 79]. Microvessels originate from afferent arterioles in the center of the islets which, in the rodents that were used in these experiments, predominantly comprise insulin-producing beta cells and direct blood flow to the islet periphery [80], a region comprising beta, alpha, delta, PP, and epsilon cells [58, 81]. Comparison of arterial and venous infusions, in the presence and absence of hormone-neutralizing antibodies, suggests that blood flow reaches beta cells first, then alpha cells, and finally delta cells [79, 80]. According to this arrangement, high concentrations of insulin should almost continuously bath the peripheral islet mantle, whereas glucagon and somatostatin would have little chance of reaching most beta cells without first entering systemic circulation. However, whether and how all islet hormones actually have any intraislet effect in vivo is still the subject of substantial debate, since we still do not know the actual
concentration of hormones in the interstitial islet fluid, the flux and direction of this fluid, and the distribution of islet cell receptors. Recent evidence has certainly provided evidence that at least insulin signaling is significant for islet function. Thus, invalidation of the gene coding for insulin receptors of pancreatic beta cells leads to mice featuring a selective loss of insulin secretion in response to glucose, which was sufficient to impair glucose tolerance [80]. Autonomic ganglia have not been observed within isolated islets [64], indicating that basal and stimulated insulin secretion may be sustained in the absence of innervation. Nevertheless, interruption of extraislet neural inputs from both parasympathetic and sympathetic fibers modifies islet function, as revealed by an increased frequency in the oscillations of insulin secretion, in rodents [2]. The rapid oscillations observed with individual, isolated islets are probably driven by periodic fluctuations in the levels of intracellular free Ca\(^{2+}\) and/or in the glycolytic activity of beta cells [61]. In vivo, these oscillations may be masked by the longer cycle pulses that result from the neural coordination of multiple islets [4, 63, 66]. Whether these considerations apply to human islets, in which the beta cell and alpha cell compartments are not as regionally distinct as in rodents [58, 81], and whose innervation also appears much sparser than in rodents [82, 83], remain to be shown.

**Ion Mediated.** Numerous other, nonhormonal or neural signals which flow through the extracellular spaces of the pancreatic islets may help coordinating beta cell behaviour. For example, it has been noted that electrophysiological characteristics are quite variable at the level of single beta cells and become more uniform and stable when these cells aggregate into clusters [61, 81, 84–87], implying an almost immediate intercellular coordination of the levels of current-carrying ions. This coordination has been verified for Ca\(^{2+}\), whose oscillatory levels appear to be determined collectively by groups of synchronized beta cells rather than by individual beta cells [61] and may rapidly equilibrate across whole islets [88, 89]. We now know that this equilibration is mostly dependent on Cx36 channels [59, 62], even though other regulatory mechanisms may modulate this essential function [3, 4]. Thus, the occurrence in the extracellular islet fluid of K\(^+\) waves, which regularly precede the bursts of electrical activity [90, 91], may provide a rapid and efficient way for coordinating the depolarization of the beta cell membranes, as well as the subsequent Ca\(^{2+}\) oscillations and insulin release in distant beta cells [6, 54, 57]. Still other islet cell interactions may involve signaling by either cytokines or NO [91–94].

**Integrin Mediated.** Numerous cell surface proteins have been identified as receptors for molecules of the extracellular matrix (ECM). Almost all of these proteins belong to the integrin family, which are receptors composed of an \(\alpha\) (120–180kDa) and a \(\beta\) subunit (90–110kDa), noncovalently bound (Figure 1). Each subunit has an extracellular domain, a single transmembrane region, and a short cytoplasmic domain associated, via a variety of cytosolic protein partners, with actin microfilaments [95]. To date, 18 \(\alpha\) and 8 \(\beta\) subunits have been identified in vertebrates, which assemble into at least 24 distinct integrin isoforms. Typically, different integrins serve as receptors for different components of the ECM (Figure 2). However, different integrins may also recognize the same ligand and, conversely, integrins composed of a same subunit may show different ligand binding specificities [95]. Integrins initiate the adhesion of cells to the substratum, on which they grow (basal lamina and ECM for epithelial cells), and organize their cytoskeleton, leading to changes in cell shape, polarity, and distribution of cellular organelles. They further activate a large variety of signal transduction events that modulate many aspects of cell behaviour, including proliferation, survival/apoptosis, shape, polarity, motility, gene expression, and differentiation [96–99]. Integrins are not endowed with enzymatic activity, but are associated with a broad variety of signaling and/or adaptor proteins involved in different signal transduction pathways. Frequently, integrin-mediated adhesion and/or clustering of integrins leads to enhanced activation of a cytoplasmic integrin-associated protein kinase, known as focal adhesion kinase (FAK) [100, 101]. A multitude of signaling molecules, including PI3K, protein kinase B (PKB/Akt), and the MAP kinase ERK, are regulated by integrin-mediated adhesion [100–102].

Adult islets of control human pancreas express \(\beta_1\), \(\alpha V\), and \(\alpha 3\) integrin subunits [101–103] (Figure 3), and the same proteins are also found, together with \(\alpha 5\) and \(\alpha 6\), in the islets of several other species [104–108]. However, while the \(\alpha 3\) subunit is restricted to islet cells, the \(\alpha 5\) subunit was expressed by both islet and acinar cells [104, 105]. Immunofluorescence revealed that the expression of \(\alpha 6/\beta 1\) integrin varied among rat beta cells, in a way which correlated with the spreading of these cells on the laminin-rich 804G matrix. This spreading was decreased by antibodies against the \(\alpha 6/\beta 1\) integrin or its \(\beta 1\) subunit, as well as by antibodies against laminin-332, one of the ligands of \(\alpha 6/\beta 1\) [106, 108]. Within rodent islets, laminin-332, together with laminin-511, type IV collagen, and numerous other laminin chains, including \(\alpha 4\), \(\alpha 5\), \(\beta 1\), \(\beta 2\), and \(\gamma 1\), form basal laminae along both islet cells and blood vessels [106, 108]. In human islets, basal laminae are split in 2 parts, with some laminin chains facing only endothelial cells and others facing only islet cells [108, 109]. The latter basal laminae are unusual in that they are rich in lutheran glycoprotein, which functions as a laminin \(\alpha\) chain receptor [109]. The data indicate that multiple receptors, recognizing many components of the ECM, ensure the adhesion and spreading of beta cells to the extracellular materials of pancreatic islets. They further document substantial differences in the composition and arrangement of basal laminae in rodent and human islets.

Insulin secretion is improved when human islet cells are cultured on a ECM made by bovine corneal endothelial cells or of type IV collagen [109, 110], rather than on standard culture plastic. This effect was associated with a decreased transcription of the insulin gene and was dependent on the activation of the ERK pathway [106, 110]. Glucose-induced insulin secretion from rat islets is also stimulated by different ECMs, including endothelial basement membranes, purified fibronectin, and the 804G matrix [111–113], in
a way that correlates with the degree of cell spreading, as a result of an upregulation in the expression of α6/β1 integrin. Thus, secretagogues elicited a higher insulin output from flattened than from spherical beta cells [106]. Comparable observations were made in cultures of canine islet cells, whose expression of α3, α5, and αV decreased with time, coincident with a decrease in proinsulin gene expression, islet insulin content, and stimulated insulin release [105]. Exposure of beta cells to antibodies blocking either the β1 integrin subunit or its laminin-332 ligand resulted in a reduction in glucose-stimulated insulin secretion when cells were attached to 804G matrix [108]. The former antibody also inhibited the phosphorylations mediated by FAK, indicating that the out-in signaling activated by the engagement of β1 integrins by laminin-332 is relevant to normal beta cell function [108]. These observations demonstrate that the islet cell-matrix interactions, mediated by specific integrins and their cognate glycoprotein ligands, modulate the sensitivity of beta cells to glucose.

The basal laminae (Figure 3) of fetal pancreatic ducts contain laminin-1, fibronectin, and collagen IV [106], and the epithelial cell clusters which bud off these ducts to begin islet morphogenesis express the cognate receptors αV/β3 and αV/β5 integrins [106]. Fetal beta-cells also express α1/β1, an integrin which is strongly induced after islet isolation and culture, and which mediates the migration of fetal beta cells on type IV collagen [106]. Parallel in vitro experiments showed that mesenchymal stem cells from umbilical cord blood can be induced to differentiate into pancreatic endocrine cells, by a mechanism which is significantly activated in the presence of ECM, and lead to the formation of three dimensional pseudoislet structures [106, 114, 115]. Proliferation of rodent islet cells is enhanced on a matrix derived from bovine corneal endothelial cells, on a collagen gel and on the 804G matrix [116–120]. While epithelial cells from fetal human pancreas also grow more rapidly on selected ECMS than on standard culture plastic [121], recent data have shown that,
after a limited numbers of years, human beta cells are no more able to proliferate in vitro, including on the 804G matrix [122], presumably due to epigenetic downregulation of key cell cycle genes. Thus, the effects of integrins and ECM on islet cell growth appear to be cell-, age-, and species-specific. In culture, the survival of isolated islets of Langerhans is prolonged in the presence of some ECM, which probably protects the microorgans from anoikis [123], and isolated beta cells are also partially protected from the apoptosis induced by serum deprivation and by interleukin-1β, when cultured on the 804G matrix. While a direct involvement of integrins in the control of beta cell viability has not yet been demonstrated, the expression of α3, α5, and αV integrins at the surface of islet cells decreases with culture time, and this change is coincident with a rise in beta cell apoptosis [105]. The mechanism underlying these effects remains to be fully elucidated. The activity of caspase-8 is reduced in islet cells cultured on ECM, under conditions that increase the activity of focal adhesion kinase (FAK), protein kinase B (PKB, or Akt), and the extracellular signal-regulated kinase (ERK). Conversely, treatment with either an anti-β1 integrin antibody, the ERK pathway inhibitor PD98059, or the phosphatidylinositol 3-kinase inhibitor LY294002 increased apoptosis in cells cultured on the 804G matrix, but not on poly-L-lysine [124]. Another study has documented that the 804G matrix induces a transient and moderate increase in the NF-kappaB activity of beta cells [116]. However, this effect is unlikely to account for the improved viability of islet cells, given that the survival of beta cells grown on the 804G matrix was not affected by inhibiting NF-kappaB phosphorylation using either Bay 11-7082, or by preventing this phosphorylation in cells transduced with an adenoviral vector encoding for a nonphosphorylatable form of IkappaB alpha [124]. These experiments indicate that the engagement of integrins with the components of the islet ECM, and notably laminin, may be crucial for islet morphogenesis, as well as for the generation and survival of differentiated beta cells. They also call for direct experiments aimed at elucidating the pathways whereby ECM protects beta cells against apoptosis.

The migration of autoreactive lymphocytes and other immune cells from the blood stream into pancreatic islets is a pathophysiological culprit in the initiation of type 1 diabetes, which may be controlled by the molecular composition of ECM and the expression of selected CAMs and integrins at the surface of both lymphocytes and endothelial cells [125]. Thus, intercellular adhesion molecule 1 (ICAM-1), which is expressed by beta cells, has also been implicated in the extravasation of lymphocytes from the circulation into the inflamed pancreas [126]. Treatment of nonobese diabetic mice with monoclonal antibodies against L-selectin and the α4 subunit of integrins protects against the spontaneous occurrence of insulitis and diabetes [127]. Furthermore, lymphocytes of inflamed islets express the α4/β7 integrin, and treatment of young diabetic mice with monoclonal antibodies against the β7 subunit of this molecule also leads to a significant and long-standing protection against the spontaneous development of diabetes and insulitis [128].

In most transplantation centers, isolated pancreatic islets are cultured 1–2 days prior to transplantation for a variety of safety and logistical reasons, as well as to improve the viability of the islets which may have been compromised by the isolation procedure. Since ECM is a native component of the islet microenvironment which positively affects islet cell function in vitro, its effects on the survival of transplanted islets have been investigated. In one study, the natural ECM of small intestine submucosa was shown to improve the secretion of isolated islets cultured for several days [129]. Also, when a polymer scaffold made of lactide and glycolide copolymers as well as collagen IV was used as a platform for islet transplantation, to mimic the 3D organization of ECM, the hyperglycemia of diabetic mice was corrected faster than in mice transplanted only with isolated islets [130]. Similar results were obtained with human islets embedded in a synthetic matrix composed of nanofibers, and transplanted into diabetic immunodeficient mice [131]. Chitosan-based artificial matrices have been recently proposed as an alternative to natural ECM for islet transplantation. In these 3D structures, the isolated islets retain the initial morphology and adequate insulin release for several weeks of culture [132]. These studies indicate that the design of an adequate and well-defined ECM microenvironment and the in vitro reestablishment of the cell-ECM interactions which normally take place within the native pancreas may be instrumental to improve the survival and function of transplanted islets.

**Pannexin Mediated.** The sequencing of mammalian genomes has revealed pannexins, a family of 3 proteins, which feature
a membrane topography analogous to that of innexins and connexins [131, 132] (Figure 1). Thus, pannexins display N- and C-terminal domains within the cytoplasm, two extracellular and one cytoplasmic loop domains, and four membrane-spanning segments. However, and in contrast to connexins, pannexins contain two Cys residues in each extracellular loop, and consensus sequences for glycosylation [133–136]. During their intracellular trafficking, 6 pannexins oligomerize to form an hexamer referred to as a pannexon, which is inserted in the cell membrane. This structure forms the wall of a hydrophilic channel which, when opened, establishes a communication between the cytosol and the extracellular fluid (Figure 2). Through pannexin channels, a variety of cytosolic molecules, including ATP, glutamate, and epoxyeicosatrienoic acid [137–139], may escape the cell and either bind to purinergic receptors on nearby cells or enter these cells, in a channel-dependent variant of paracrine cell-to-cell communication. At least in vitro, the pannexon channels also allow cells to rapidly incorporate molecules present in the extracellular fluid, by a gradient-dependent diffusion mechanism [140–144]. In contrast, and probably because of the glycosylated residues, the pannexons of one cell cannot approximate those of an adjacent cell sufficiently close to establish a cell-to-cell channel [135, 136, 142, 143, 145–147]. Pannexin channels are activated by mechanical stress [148–151], large depolarizations, and activation of purinergic receptors [138, 152–159]. These channels have now been implicated in a number of physiological functions, including gene expression, propagation of calcium waves, vasodilation, taste sensation, and immune response [160]. The proteins have also been implicated in a variety of pathophysiological conditions, including cell death, and tumorigenesis [160–162].

Little is known about the function of pannexins in pancreatic islets, beside the finding of transcripts coding for both Pnx-1 and Pnx-2 (unpublished). While cell purification studies indicate that beta-cell-rich fractions predominantly express the RNA of Pnx2, whereas the nonbeta-cell-rich fractions predominantly express the transcript of Pnx-1 (unpublished; Figure 3), neither the cell distribution nor the levels of the cognate proteins are yet established, mostly because of the modest quality of the existing antibodies. In view of the many similarities between beta cells and neurons, a prediction would be that Pnx-2 is selectively expressed by beta cells. Given that these channels can be permeated by glutamate, a putative beta-to-alpha paracrine signal [163], such channels could operate in coordinating the antagonistic insulin and glucagon secretions. Even though the beta-alpha cell interactions have been usually attributed to paracrine communication, a hormonal signaling cannot alone account for all conditions under which beta and alpha cells function antagonistically [51, 53, 163]. The comparison of wild type and pannexin null [161, 164] mice is expected to provide clues about this possibility. At this point, tracer and ATP release experiments have not yet demonstrated that functional Pnx channels operate in isolated mouse islets [147] a negative finding that should take into account that these channels have a rather small conductance and a quite low open probability [160].

5.3.2. Direct Interactions. In spite of some dynamic and quantitative alterations, glucose-induced insulin release is preserved under in vitro conditions which perturb the inner-regulation, blood supply, and flux of extracellular fluid which, in vivo, mediate the indirect communications between islet cells, discussed in the previous sections. In contrast, physical separation of the islet cells leads to a rapid loss of this regulation, which is at least partially reversible soon after the reestablishment of cell contacts [6, 7, 51, 57]. Hence, maintenance of regulated secretion is dependent on the preservation of at least some of the contacts beta cells established within native pancreatic islets [6, 7, 51, 57]. Three modalities of the direct cell-to-cell communication with contact permits operate within pancreatic islets.

Receptor/Ligand Mediated. By bringing cell membranes in close proximity, contact between beta cells allows for the interaction of surface receptors featured by one cell, with surface ligands carried by an adjacent cell. Thus, invalidation of the gene coding for either the insulin or the Igf1 receptor of beta cells unexpectedly resulted in defective glucose-stimulated insulin secretion and impaired glucose tolerance [80, 165], presumably because the intra-islet signaling provided by insulin in either an autocrine and/or paracrine manner is interrupted. A severe impairment of glucose-induced insulin release is also observed after interference with the EphA- and Fas-dependent pathways of β-cells, presumably due to perturbed interaction between one of these two receptors and its cognate ligand [166, 167].

Cell Adhesion Molecule Mediated. Most cell types adhere to each other by a variety of single pass, transmembrane proteins, referred to as cell adhesion molecules (CAMs) [168] (Figure 1). Most CAMs are functionally dependent on extracellular Ca\(^{2+}\) and thus are referred to as cadherins. These glycoproteins, which have a molecular mass of about 120 KDa, form a family including E, P, N, and R isoforms [169, 170]. The homophilic interaction between cadherins is initiated through dimerization of two cadherin molecules in the membrane of one cell, followed by the homologous interaction of the extracellular domains of one dimer, with the corresponding moieties assembled by an adjacent cell. In the presence of Ca\(^{2+}\), the dimers intermingle as the teeth of a zipper, ensuring a stable and strong cell-to-cell adhesion. The intracellular domains of classical cadherins interact with actin myofilaments via several cytosolic proteins, including α-actinin, β-catenin, γ-catenin, and p120 [171]. Cadherins control cell-to-cell adhesion (Figure 2) and, thus, are central to the establishment and maintenance of multicellular organisms. During prenatal development, these molecules play a role in differentiation and morphogenesis of many tissues. In adults, cadherin interactions allow for maintenance of cell polarity and tissue architecture and regulate a variety of functions, including cell growth, motility, and viability. Cell signaling events involving small GTPases of the Rho family have also been shown to be regulated by cadherin engagement [172, 173] (Figure 2). Other CAMs, such as N-CAM, ensure cell-to-cell adhesion independently of Ca\(^{2+}\) [173, 174]. N-CAM belongs to the immunoglobulin superfamily and is
expressed as 3 distinct isoforms. Two of these isoforms are transmembrane proteins with either a short (N-CAM140) or long (N-CAM180) cytoplasmic domain. The third isoform (N-CAM120) has no cytoplasmic domain and is anchored by glycophasphatidylinositol to the plasma membrane. All three isoforms are posttranslationally modified by the addition of polysialic acid [171, 175]. This glycosylation is regulated during development, decreasing from the embryonic to the adult age [174], in parallel with decreased strength of cell adhesion.

Multiple CAMs are expressed in pancreatic islets (Figure 3). N-CAM140 is preferentially found in the non beta cell fraction [168, 174], whereas E-cadherin is the predominant CAM of beta cells [176, 177] (Figure 4). N- and R-cadherins, as well as Ep-CAM have been described in developing, but not adult islets [178–180]. These data show that variable levels of various CAMs, of both Ca<sup>2+</sup> dependent and independent groups, are expressed by the main endocrine islet cells. This differential expression presumably accounts for the developmental segregation of the hormone-producing cells of pancreas. Thus, both N-CAM and R-cadherin have been detected in the early fetal development of the gastrointestinal pancreatic system, in which they are rapidly segregated into developing islets and related pancreatic ducts, respectively, while being undetectable in the nearby exocrine acini [178, 179]. Later on, R-cadherin decreases in clustered islet cells and becomes undetectable in fully formed islets of Langerhans [181]. Ep-CAM is also thought to have a morphogenetic role in the human pancreas [180]. Thus, high levels of this molecule are found in the growing fetal duct cells which may comprise islet progenitors, as well as in other types of proliferating epithelial cells. In contrast, cells that had started differentiating towards a beta cell phenotype feature low levels of this glycoprotein, which is no more detected in adult human islets [180]. Consistently, antibody blockade of Ep-CAM function promotes the differentiation of fetal human beta cells in culture [180].

Rodent pancreatic islets are consistently organized as a core of beta cells surrounded by a peripheral mantle of non beta cells. This specific topographic arrangement is largely dependent on a differential expression of distinct CAMs by beta (E-cadherin > PSA-N-CAM > N-CAM) and non beta cells (E-cadherin > N-CAM). Thus, single islet cells rapidly and spontaneously reaggregate into tri-dimensional organoids, or pseudo-islets, which feature a cellular organization alike that of native islets [182, 183], and this arrangement is perturbed when the reaggregation takes place in the presence of antibodies against N-CAM [184–186]. Over-expression in beta cells of a dominant negative E-cadherin, lacking most of the extracellular domain which is essential for homophilic interaction, abolished the expression of the native cadherin, resulting in defective clustering of beta cells, while alpha cells properly segregated into islet-like structures [187]. Another transgenic mouse, which features diabetes and impaired glucose-stimulated insulin secretion as a result of defective expression of hepatocyte nuclear factors, showed reduced islet expression of E-cadherin [188, 189]. As a result, pancreatic islets also had an altered architecture, with alpha cells scattered throughout both mantle and core of the microorgans [188, 189]. These data strongly support the view that specific CAMs control, at selected developmental stages, the adhesion of endocrine cells into islets and the precise organization of different cell types within these endocrine units. Given, the quite different organization of human pancreatic islets, in which small groups of beta cells appear intermixed with alpha cells and other cell types, which are more abundant than in rodents [190], it remains to be determined to what extent the CAM-dependent sorting also controls the spatial distribution of human islet cells.

It is well established that insulin secretion from aggregated beta cells is significantly higher than that from an equal number of dispersed cells [72, 73, 76, 78, 191, 192]. Several independent lines of evidence also support the view that beta cells form a functionally heterogeneous population, in terms of insulin biosynthesis and secretion, and that this heterogeneity is compensated within clusters and intact islets, as a result of the establishment of homologous beta
cell contacts [6, 51, 57, 76–78]. The sialylated form of N-CAM (PSA-N-CAM) is expressed at different levels in highly and poorly glucose-responsive beta cells [177, 191]. After shedding of PSA using endoneuronaminidase N, the recovery of PSA-N-CAM at the beta cell surface was rapidly observed under conditions stimulating insulin secretion, consistent with the localization of the molecule into secretory granules, and its translocation to the cell surface during exocytosis [177]. Interestingly, N-CAM null mice also feature degranulated beta cells, consistent with a role of this CAM in the normal turnover of insulin secretory granules [186]. Insulin secretagogues also promote the expression of E-cadherin in parallel with an increase in the aggregation of rat beta cells and in their glucose-induced insulin secretion [192]. Also, the release of insulin from cultures of MIN6 cells grown in three-dimensional islet-like aggregates was higher than that of the same cells grown in monolayers [193]. RNAi-mediated silencing of E-cadherin resulted in a decreased glucose-stimulated secretion, which was reduced to the levels observed in isolated cells [194], and exposure of MIN6 cells to an anti-E-cadherin antibody abolished the glucose-induced increase in cytosolic free calcium [188]. The same antibody also abolished the glucose-stimulated insulin secretion of isolated islets [195]. Still, it is worth noting that the positive effect of E-cadherin on insulin secretion was not confirmed in another study that compared clones of MIN6 cells over- and underexpressing the CAM. These clones did not differ in terms of glucose-induced insulin secretion, even though the levels of preproinsulin mRNA and insulin content, as well as the basal rate of insulin release were higher in over- than in under-expressing cells [196, 197]. These data support the view that CAMs control the postnatal functioning of beta cells, notably by modulating glucose-induced insulin secretion. However, because changes in E-cadherin expression affect the expression of other surface proteins, notably Cx36 [197, 198], the specificity of the CAM-dependent control remains to be established.

Loss of E-cadherin parallels the transition from a well differentiated adenoma to an invasive carcinoma, in a transgenic mouse model of pancreatic beta cell carcinogenesis [199]. In this model, the normal 140-kDa isoform of N-CAM decreases while a 120/180-kDa isoform, which is not expressed in native islets, increases [200]. Under these conditions, the blockade of N-CAM expression favored the development of metastases, suggesting a role of N-CAM in the pathologic dissemination of tumoral beta cells [200]. In pseudo-islets made of transformed MIN6 cells, E-cadherin over expression is associated with increased expression of cyclin-dependent kinase inhibitors, and with a decrease in the cell proliferation marker Ki67, consistent with a role of E-cadherin in some antiproliferation mechanisms [196, 201]. During mouse islet formation, E-cadherin expression increases with the decline in the proliferation rate of beta cells, due to a selective down-regulation of nuclear β-catenin and D-cyclins [198]. Together, these data suggest that E-cadherin and N-CAM may contribute to control beta cell proliferation. However, whether such a contribution has any relevance for the minimal, physiological growth of native beta cells remains to be validated, specifically in humans. Intriguingly, the CDH1 gene, which encodes human E-cadherin, is located on chromosome 16q22.1, a locus that has been implicated in susceptibility to type 1 diabetes [202], and various CAMs have been implicated in the autoimmune pathogenesis of type 1 diabetes [125–128, 203].

CD8+ lymphocytes mediate the rejection of pancreatic islet allografts [203]. Some of these cells, referred to as CD103, express the integrin αE(βCD103)-β7, whose only known counterreceptor is E-cadherin [204]. After allotransplantation of control islets, which express E-cadherin, wild type CD103+/− mice rapidly rejected the grafts. In contrast, these grafts indefinitely survived in host CD103−/− mice, which feature a targeted disruption of CD103 [205]. Transfer of CD8+ cells into host CD103−/− mice, caused a prompt rejection of the islet allografts, whereas the transfer of CD103−/− and CD8−/− cells had no effect [205]. These results imply that a direct interaction between selected CAMs expressed by both immunocompetent and islet cells may be an important determinant in the acceptance or rejection of a transplanted graft. In turn, this consideration opens the interesting possibility that the engraftment and maintenance of functional islet grafts could be enhanced by a selective modulation of their major CAMs.

### Claudin Mediated.

The 24 members of the claudin family and the 2 isoforms of occluding, which are often associated to claudins, are tetraspan membrane proteins, which feature two extracellular loops, four transmembrane α-helices portions, two cytoplasmic loops, and both N- and C-termini in the cytoplasm [206, 207] (Figure 1). The carboxy terminus of these molecules interacts with different attachment proteins of the ZO, JAM, and cingulin families, each of which comprises multiple isoforms, which functionally interconnect claudins and occludins to the actin microfilaments of the cytoskeleton [207, 208]. Claudins and occludin concentrate at points of focal contact between adjacent cell membranes to form tight junctions. These structures prevent the movement of proteins and lipids between the apical and the basolateral regions of the plasma membrane, thus providing for the structural and functional segregation of these two regions [206, 208] which contributes to cell polarity (Figure 2). By preventing the free diffusion of fluids, solutes and cells across the paracellular space, tight junctions also contribute to impart a selective permeability to groups of epithelial cells. Tight junctions are functionally heterogeneous and form plastic structures whose selective permeability, which varies with their claudin composition, may be modulated by various kinase-dependent mechanisms, triggered by both CAMs and intracellular signals [206, 208]. They further functionally interact with a variety of cytosolic proteins, notably the members of the ZO and JAM families, as well as with tumor suppressor proteins, such as the membrane-associated guanylate kinases [209], indicating that they contribute to cell signaling (Figure 2).

Electron microscopy of pancreatic islets in situ has documented sites of contacts between beta cell membranes, which feature all the ultrastructural aspects of bona fide tight junctions [210] (Figures 3 and 5). Accordingly, typical tight
membranes of adjacent functional evidence exists that islet tight junctions delimit junctions—brils have been documented by freeze fracture heads) within the bilayer of a microscopy of such a site reveals clusters of Cx36 channels (arrow heads). (b): freeze-fracture electron electronlucent extracellular space, which is markedly narrowed at typical insulin-containing granules, are usually separated by an are rich in hormonereceptorsandglucosetransporters,from those where exocytosis of the insulin-containing secretory granules takes place [79]. Evidence in support of the presence of islet tight junctions also include their rapid in vitro modulation [214]. Recently, the expression of some claudins has been reported in genome-wide analysis of islet transcripts, and a major surge of a specific claudin mRNA has been documented in pancreatic islets of pregnant rodents [215, 216]. This unanticipated and striking observation indicates that at least some claudins participate to the islet function in vivo. Given that, during pregnancy, beta cells rapidly modify their mass and insulin secretion to adapt to the increased metabolic demand imposed by the foetus growth [217, 218], a careful experimental approach should now test what may be the claudin/tight junction involvement in these structural and functional adaptations.

Connexin Mediated. Twenty genes coding for as many connexins (Cx) are found in the human genome, over a large number of chromosomes [6, 35–39]. All connexins feature four membrane-spanning domains linked by two extracellular and one intracellular loop, and cytoplasmic N- and C-terminal regions (Figure 1). The N-terminus, the two extra-cellular loops, and the four transmembrane domains, which form α-helices, have been highly conserved during evolution. In contrast, the intracellular loop and the C-terminus are highly variable [6, 35–39]. Six connexin molecules, of the same or a different type, assemble during their intracellular transport from the ER to the cell membrane, to form the wall of hydrophilic channels [6, 35–39]. After a vesicle-mediated insertion into the cell membrane, these channels concentrate in small domains referred to as gap junctions. At these sites, the intercellular space is reduced to a “gap” of about 2 nm, and the connexons of two adjacent cells join end-to-end, within the extracellular space, to form a junctional channel. Connexin channels are permeable to a variety of ions and larger molecules, including cytosolic metabolites, nucleotides, morphogens, vitamin cofactors, small peptides, and fragments of nucleic acids [1, 4–6]. At gap junctions, the passage of these molecules from one cytoplasm to another is referred to as ionic and metabolic coupling, respectively (Figure 2). The conductance and permeability of both junctional channels and “hemichannels” are highly selective [6, 35–39], as a function of both their Cx composition, and the size, shape, and charge of the permeant molecule [6, 35–39]. Cx channels are open only about 10% of the time and again, depending on their Cx composition, may be gated by transjunctional voltage, cytosol acidification or an increase in free cytosolic Ca²⁺ [1, 4–7]. Gap junction channels have been implicated in the prenatal development, morphogenesis, and differentiation of many tissues, as well as in several functions of adult systems, including cell division and migration, hormonal transmission, electrical and mechanical synchronization, secretion, resistance to cytotoxic agents, compensation of enzymatic defects, and transmission of trophic or deadly molecules [6, 35–39, 57]. The in vivo relevance of the Cx functions is supported by the specific phenotypes observed in transgenic mice featuring a knock-in, knockout, or a mutation of selected connexins [6, 35–39, 219, 220]. It is further stressed by the finding of several human diseases which are associated to either Cx mutations or synonymous single nucleotide polymorphisms [6, 35–39, 219, 220].

Beta cells are electrically and metabolically coupled by small gap junctions (Figure 4) made of Cx36 [6, 51, 57, 62, 221–230] (Figures 3–5). The electrical coupling encompasses the entire islet, as indicated by the rhythmic and synchronized bursts of electrical activity as well as by the coordinated Ca²⁺ oscillations that are observed during glucose-induced insulin secretion in most beta cells [85, 87, 223, 231–233]. In contrast, the metabolic coupling may be more restricted, since gap junction tracers are only exchanged by small groups of beta cells [59, 227, 229, 230, 234]. Loss of Cx36, after either homologous recombination of the Gja9 gene.
or its conditional deletion in beta cells, results in complete beta cell uncoupling and loss of gap junctions, ruling out compensation by another Cx isoform [65, 222, 226, 233, 235, 236]. Single beta cells, which can no more be coupled by Cx36 channels, show decreased basal expression of the insulin gene, and reduced proinsulin biosynthesis [236, 237]. Gap junction size correlates with the insulin content of pancreas in rats treated with a sulphonylurea [211, 238]. A correlation has also been documented between the expression of Gjδ2, the gene which codes for Cx36, and the gene coding for insulin [234, 239, 240]. In the developing mouse pancreas, expression of Cx36 is initially detected at the time the first wave of insulin-producing beta cells is induced [240]. This temporal association is due to the transactivation of Gjδ2 by Beta2/NeuroD1, a transcription factor which is also essential for beta cell differentiation and maturation [241]. Single beta cells also show increased basal release of insulin, and poor to nil glucose-induced insulin release, and elevation in free cytosolic calcium [75, 232, 242–246]. Several of these effects are rapidly reversible after reaggregation [75, 232, 242–246]. Clustering also promotes the recruitment of secretory and biosynthetically active beta cells [77, 237, 243–245]. Comparable conclusions were reached by exposing intact islets to Ca\(^{2+}\) transients induced by glucose stimulation [62, 222, 226, 248]. These islets also show increased basal release of insulin [62, 222, 226, 248], which is a pancreas autonomous defect [222, 231]. The excessive basal secretion is consistent with the finding that uncoupled beta cells can no more be inhibited by hyperpolarizing currents generated in nearby, resting cells [226, 248], and with the prolonged decay in the off response of beta cells once the glucose stimulation stops [226]. The loss of glucose responsiveness is consistent with that of the regular oscillatory output of insulin during both the first and the second phases of insulin release [62, 222, 226, 248]. In mice, loss of Cx36 does not cause overt diabetes [62, 222, 233], but causes intolerance to post-prandial glucose levels as a result of the in vivo decrease in the oscillations of circulating insulin [233]. This decrease is associated with alterations in the amplitude and decay [226] of the first phase of glucose-induced insulin secretion, as well as with reduced insulin oscillations during the second phase [233]. The data indicate that Cx36 occupies a prominent hierarchical position in the multifactorial regulation of insulin dynamics, which is central to glycemic control [2, 249].

In vivo, loss of Cx36 sensitizes beta cells to pharmacological and immunological insults, including by the cytokines which induce apoptosis at the onset of type 1 diabetes [235]. Conversely, transgenic mice overexpressing Cx36, or other Cx isoforms, appear fully protected against the same insults [235]. The mechanism of this protection, which may be partially explained by the extent of beta cell coupling, remains to be fully elucidated. Cx36 may also contribute to the regulation of the beta cell mass, given that apoptosis is a major determinant of beta cell life, and that beta cell coupling is enhanced by hormones prevailing during pregnancy [250], a condition associated with a marked increase in beta cell proliferation and reduced apoptosis. This effect, however, is neither direct, nor linear [62, 222, 251].

Cx channels permit a rapid, diffusion-driven, and bidirectional exchange of molecules between coupled cells, a mechanism that rapidly results in the equilibration of mass and electrical gradients [6, 51]. Thus, compared to other mechanisms of cell-to-cell communication, Cx coupling is advantageous in systems in which cell heterogeneity could conceivably result in the asynchronous function of individual cells [6, 51]. Beta cells differ in a number of structural, biochemical, and functional respects, including in terms of the biosynthesis, storage, and release of insulin [4, 6, 57, 77, 219, 228, 232, 242–244, 249–257]. Under such conditions, coupling allows for the recruitment of increasing numbers of secretory cells with both cell aggregation and the degree of stimulation [77, 232, 242–244, 249–254], presumably by counterbalancing the asynchronous function of intrinsically heterogeneous beta cells. In the absence of coupling, such an asynchrony would most likely impair the timely production and release of sufficient amounts of insulin to maintain normoglycemia. The lack of detectable phenotype in heterozygous mice of the Cx36 null and the beta cell Cx36 depleted strains indicates that normoglycemia can be preserved with half the native levels of Cx36 [62, 222, 233, 235]. Estimations based on the minimal conductance of Cx36 channels, required to preserve the intercellular synchronization of the glucose-induced Ca\(^{2+}\) transients, indicate that Cx36 signaling is impaired when about 70% of the native Cx36 levels are lost [233]. The reason why normal beta cells need to be coupled is most likely due to the functional heterogeneities of these cells, with respect to multiple structural, biochemical, and functional parameters, notably insulin biosynthesis and secretion [4, 6, 57, 219, 228, 255–257].

Coupling may also represent a protective mechanism for beta cells, inasmuch as the irregular Ca\(^{2+}\) oscillations, which result from loss of Cx36, could conceivably alter the expression of specific beta cell genes, and the resistance of beta cells to apoptosis [235, 256]. These findings support the notion that glucose-induced insulin secretion is critically dependent on the signaling mediated by beta-to-beta cell contacts. The further finding of Cx36 alterations in experiments testing the effects of the E-cadherin- [193, 197, 198] and EphA-dependent pathways [166] further suggests that Cx36 may be a common partner of several signaling mechanisms which operate within the islets, possibly by providing for their cross-talk and/or final, distal effects.
Cx36 only forms homomeric and homotypic intercellular channels [6, 35–39], preventing coupled beta cells to share with other cell types the cytosolic signals they need to exchange for coordinating their own activity. Such selectivity is appropriate for proper islet functioning, particularly since beta and alpha cells function antagonistically under most conditions. Gap junctions have been claimed to connect different islet cell types [258], which are occasionally coupled in culture [259, 260]. However, direct evidence that alpha and beta cells make bona fide gap junction plaques has not yet been provided, and tracer studies do not support the occurrence of a large coupling between these cells [261–263]. In addition, while both alpha and beta cells feature Ca\(^{2+}\) oscillations which are synchronized with those of companion cells, the synchronization of alpha cell oscillations is asynchronous with that of beta cells, in both rodent and human islets [63, 262, 264], implying lack of simultaneous Cx36-dependent coupling between the two cell types. Still, since most secretory cell types express at least one connexin [6, 57], it is not clear why pancreatic alpha cells would be an exception. The regular oscillations of glucagon secretion [63, 263] rather suggests that alpha cells are also coupled, by a mechanism which remains to be unravelled.

The phenotype of mice largely or totally depleted in Cx36 shows several beta cell alterations which are typical of glycemia disorders, including loss of circulating insulin oscillations, glucose intolerance, increased basal secretion, decreased first and second phase of glucose-induced insulin secretion, and increased beta cell apoptosis [51, 62, 235, 248, 252, 256]. Since human beta cells are also coupled by Cx36 [234], whose encoding gene is located in chromosome 15q14 [265], a locus associated with type 2 diabetes [266], an intriguing possibility is that alterations in Cx36 signaling may be implicated in the loss of beta cell function and mass seen in the human clinic [267]. This is further supported by the finding that the expression of Cx36 is down-regulated after chronic exposure to several circulating molecules which contribute to the pathogenesis of these disorders, including high levels of glucose, fatty acids, oxidized low density lipoproteins, and cytokines [235, 268–270]. If there is yet no human evidence for a pathogenic role of Cx36, this concept is supported by several animal and a couple of genetic studies. Mice developing glucose intolerance, obesity, peripheral insulin resistance, hyperglycemia, hyperinsulinemia, and increased beta cell mass after a high fat diet feature decreased glucose-induced insulin secretion, Cx36 expression, and beta cell coupling [240]. Mice invalidated for Gjd2 feature alterations in beta cell function which are reminiscent of those that precede the development of overt diabetes in humans (e.g., loss of insulin oscillations) and, later, characterize the disease (e.g., increased basal release of insulin and failure to increase the insulin output in the presence of postprandial concentrations of glucose) [51, 62, 235, 248, 252, 256]. A single nucleotide polymorphism in the coding sequence of GJD2 has been shown to be pathogenic in a form of epilepsy which shares with type 2 diabetes a complex inheritance pattern [271, 272], indicating that subtle genetic Cx36 changes may be pathogenic in humans. A defect in Cx36 signaling could be further enhanced by alterations of circulating nutrients, notably long-term hyperglycemia, and hyperlipidemia, which negatively affects Cx36 expression [267–270]. In mice, the levels of Cx36 correlate with the in vivo resistance of \(\beta\)-cells to conditions reproducing the apoptosis observed at the onset of type 1 diabetes [253, 256]. Whether this is due to a Cx36-dependent enhancement of their resistance and/or to improved repairing mechanisms remains to be determined. Consistent with these findings, Th1 cytokines decrease Cx36 expression at the transcriptional level [256], and altered expression of the Cx36 transcript has been detected in genome-wide scans of type I diabetes models [257, 273].

In view of the above, the question arises whether we could take advantage of Cx biology to develop innovative therapeutic approaches to glycemic disorders. Strikingly, a sulphonylurea, which stimulates insulin release from beta cells of type 2 diabetics, also promotes the assembly of Cx36 channels and improves beta cell coupling [211, 227, 238, 249, 274], opening the search for other innovative molecules targeting Cx36 [274]. This connexin is also likely not to be disposable for the forthcoming implementation of cell therapies using surrogate insulin-producing cells to replace the lost or damaged beta cells. This replacement implies that the transplanted cells become functionally integrated within the host tissue, which presumably will involve the development of appropriate Cx36-dependent cell interactions. The embryonic stem and progenitor cells which have so far been tested in this perspective, with modest results in terms of yield of clinically useful insulin-containing cells, lack Cx36 [275–277]. Recently, the forced expression of this connexin isoform has been reported to foster the differentiation of neurons from progenitor cells [278]. Whether the same might apply to beta cells, which share many common features with neurons, including Cx36 expression, remains to be shown.

6. The Present and the Future

The beta cells collectively function as a multicellular system and, as such, are functionally integrated within pancreatic islets by a variety of mechanisms of indirect and direct cell-to-cell communication. We now know that many of the latter mechanisms involve distinct families of integral membrane proteins, which interact, and in part functionally overlap, to ensure the proper function of pancreatic islets. Whether this is due to a Cx36-dependent enhancement of beta and alpha cell functions? What is their hierarchical position in the intricate network of pathways that support the vital insulin and glucagon production? Are these proteins causally implicated in glycemia disorders, and specifically in type 1 and type 2 diabetes? Are they altered in expression and/or functioning as a consequence of these diseases? Could we take benefit of these proteins to develop innovative therapeutic approaches to beta cell diseases? Many challenges and hurdles will undoubtedly complicate the experimental
approaches to these questions, particularly in vivo and in humans. Still, the challenge is worthwhile, since answering some of these questions is likely to provide novel views on how the pancreatic beta cells interact to ensure proper control of blood glucose and metabolism. In an optimistic perspective, we expect that such a knowledge would set the basis for molecular and cellular targeted treatments of the related disorders, which have an extremely high medical, social and economic cost and have now reached epidemic proportions worldwide.

Acknowledgments

The author is supported by Grants from the Swiss National Science Foundation (310000-109402, CR3213_129987, and IZ73Z0_127935), the Juvenile Diabetes Research Foundation (40-2011-11 and 99-2012-775), and the European Union (BETAIMAGE 222980; IMIDIA; C2008-T7 and BETATRAIN 289932).

References

[1] D. LeRoith, G. Delahunty, G. L. Wilson et al., "Evolutionary aspects of the endocrine and nervous systems," Recent Progress in Hormone Research, vol. 42, pp. 549–587, 1986.
[2] P. Bergsten and B. Hellman, "Glucose-induced amplitude regulation of pulsatile insulin secretion from individual pancreatic islets," Diabetes, vol. 42, no. 5, pp. 670–674, 1993.
[3] P. Gilon, M. A. Ravier, J. C. Jonas, and J. C. Henquin, "Control mechanisms of the oscillations of insulin secretion in vitro and in vivo," Diabetes, vol. 51, supplement 1, pp. S144–S151, 2002.
[4] A. Tengholm and E. Gylfe, "Oscillatory control of insulin secretion," Molecular and Cellular Endocrinology, vol. 297, no. 1-2, pp. 58–72, 2009.
[5] J. C. Henquin, "Regulation of insulin secretion: a matter of phase control and amplitude modulation," Diabetologia, vol. 52, no. 5, pp. 739–751, 2009.
[6] D. Bosco, J. A. Haefliger, and P. Meda, "Connexins: key mediators of endocrine function," Physiological Reviews, vol. 91, pp. 1393–1445, 2011.
[7] P. Meda, "Intercellular communication and insulin secretion," in Contributions of Physiology to the Understanding of Diabetess, G. R. Zahnd and C. B. Wollheim, Eds., pp. 24–42, Springer, Berlin, Germany, 1997.
[8] J. P. Trinkaus, Cells into Organs. The Forces That Shape the Embryo, Prentice-Hall, Englewood Cliffs, NJ, USA, 1984.
[9] G. M. Edelman and J. P. Thiery, The Cell in Contact. Adhesions and Junctions as Morphogenetic Determinants, John Wiley and Sons, New York, NY, USA, 1985.
[10] J. R. Henderson, "Why are the islets of Langerhans?" The Lancet, vol. 2, no. 7618, pp. 469–470, 1969.
[11] J. W. Schopf, "Microfossils of the early Archean Apex Chert: new evidence of the antiquity of life," Science, vol. 260, no. 5108, pp. 640–646, 1993.
[12] J. T. Bonner, First Signals: The Evolution of Multicellular Development, Princeton University Press, Princeton, NJ, USA, 2001.
[13] J. T. Bonner, "A way of following individual cells in the migrating slugs of Dictyostelium discoideum," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 16, pp. 9355–9359, 1998.
[14] J. T. Bonner, "The origins of multicellularity," Integrative Biology, vol. 1, pp. 27–36, 1999.
[15] J. Gerhart and M. Kirschner, Cells, Embryos and Evolution, Blackwell Science, Malden, Mass, USA, 1997.
[16] J. Gerhart and M. Kirschner, "The theory of facilitated variation," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, supplement 1, pp. 8582–8589, 2007.
[17] J. Gerhart, C. Lowe, and M. Kirschner, "Hemichordates and the origin of chordates," Current Opinion in Genetics and Development, vol. 15, no. 4, pp. 461–467, 2005.
[18] A. Rokas, "The molecular origins of multicellular transitions," Current Opinion in Genetics and Development, vol. 18, no. 6, pp. 472–478, 2008.
[19] A. Rokas, "The origins of multicellularity and the early history of the genetic toolkit for animal development," Annual Review of Genetics, vol. 42, pp. 235–251, 2008.
[20] L. Wolpert and E. Szathmáry, "Multicellularity: evolution and the egg," Nature, vol. 420, no. 6917, article 745, 2002.
[21] J. T. Bonner, Why Size Matters: From Bacteria to Blue Whales, Princeton University Press, Princeton, NJ, USA, 2006.
[22] L. W. Buss, "Slime molds, ascidians, and the utility of evolutionary theory," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 8801–8803, 1999.
[23] L. Bull, "On the evolution of multicellularity and eusociality," Artificial Life, vol. 5, no. 1, pp. 1–15, 1999.
[24] R. E. Michod and D. Roze, "Cooperation and conflict in the evolution of multicellularity," Heredity, vol. 86, no. 1, pp. 1–7, 2001.
[25] H. A. Bern, "The properties of neurosecretory cells," General and Comparative Endocrinology, vol. 1, supplement 1, pp. 117–132, 1962.
[26] R. K. Campbell, N. Satoh, and B. M. Degnan, "Piecing together evolution of the vertebrate endocrine system," Trends in Genetics, vol. 20, no. 8, pp. 359–366, 2004.
[27] A. Gorbman, W. D. Dickoff, S. R. Vigna, N. B. Clark, and C. A. Gorbman, "Molecules of intercellular communication in Dictyostelium discoideum and E. coli as the Maginot lines of the immune system," Nature, vol. 360, no. 6403, pp. 541–546, 1992.
[28] D. LeRoith, J. Shiloach, J. Roth, and M. A. Lesniak, "Evolutionary origins of vertebrate hormones: substances similar to mammalian insulins are native to unicellular eukaryotes," Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 10, pp. 6184–6188, 1980.
[29] D. LeRoith, C. Roberts, M. A. Lesniak, and J. Roth, "Receptors for intercellular messenger molecules in microbes: similarities to vertebrate receptors and possible implications for diseases in man," Experientia, vol. 42, no. 7, pp. 782–788, 1986.
[30] J. Roth, D. Leroith, and E. S. Collier, "The evolutionary origins of intercellular communication and the Maginot lines of the mind," Annals of the New York Academy of Sciences, vol. 463, pp. 1–11, 1986.
[31] J. Roth, D. LeRoith, and E. S. Collier, "Evolutionary origins of neuropeptides, hormones, and receptors: possible applications to immunology," Journal of Immunology, vol. 135, supplement 2, pp. 816s–819s, 1985.
[32] J. Roth, D. LeRoith, M. A. Lesniak, F. de Pablo, L. Bassas, and E. Collier, "Molecules of intercellular communication in vertebrates, invertebrates and microbes: do they share common origins?" Progress in Brain Research, vol. 68, pp. 71–79, 1986.
[33] F. M. Ashcroft, Ion Channels and Disease, Academic press, San Diego, Calif, USA, 2000.
[34] S. Bröer and C. A. Wagner, Membrane Transporter Diseases, Kluwer Academic, New York, NY, USA, 2003.
[35] A. Harris and D. Locke, Connexin Biology: The Role of Gap Junction in Disease, The Humana Press, Totowa, NJ, USA, 2008.
[36] A. L. Harris, "Emerging issues of connexin channels: biophysics fills the gap," Quarterly Reviews of Biophysics, vol. 34, no. 3, pp. 325–472, 2001.
[37] J. C. Hervé, "The connexins, part II," Biochim Biophys Acta, vol. 1711, pp. 97–246, 2005.
[38] J. C. Hervé, "The connexins, part III," Biochim Biophys Acta, vol. 1662, pp. 1–172, 2004.
[39] J. C. Hervé, "The connexins, part IV," Biochim Biophys Acta, vol. 1719, pp. 1–160, 2005.
[40] E. J. W. Barrington, "The phylogeny of the endocrine system," Experientia, vol. 42, no. 7, pp. 775–781, 1986.
[41] K. L. Becker, E. S. Nylen, and R. H. Snider, "Endocrinology and the endocrine patient," in Principles and Practice of Endocrinology and Metabolism, K. L. Becker, Ed., pp. 2–13, J.B. Lippincott, Philadelphia, Pa, USA, 1990.
[42] A. M. Stoka, "Phylogeny and evolution of chemical communication: an endocrine approach," Journal of Molecular Endocrinology, vol. 22, no. 3, pp. 207–225, 1999.
[43] J. E. Blalock and J. D. Stanton, "Common pathways of interferon and hormonal action," Nature, vol. 283, no. 5745, pp. 406–408, 1980.
[44] J. E. Blalock, "A molecular basis for bidirectional communication between the immune and neuroendocrine systems," Physiological Reviews, vol. 69, no. 1, pp. 1–32, 1989.
[45] J. Roth, D. LeRoith, and J. Shiloach, "The evolutionary origins of hormones, neurotransmitters, and other extracellular chemical messengers. Implications for mammalian biology," The New England Journal of Medicine, vol. 306, no. 9, pp. 523–527, 1982.
[46] B. Scharrer, "Peptidergic neurons: facts and trends," General and Comparative Endocrinology, vol. 34, no. 1, pp. 50–62, 1978.
[47] H. A. Bern, "The properties of neurosecretory cells," General and Comparative Endocrinology, vol. 1, supplement 1, pp. 117–132, 1962.
[48] G. Csaba, "The present state in the phylogeny and ontogeny of hormone receptors," Hormone and Metabolic Research, vol. 16, no. 7, pp. 329–335, 1984.
[49] S. Falkmer, "Phylogeny and ontogeny of the neuroendocrine cells of the gastrointestinal tract," Endocrinology and Metabolism Clinics of North America, vol. 22, no. 4, pp. 731–752, 1993.
[50] S. van Noorden and S. Falkmer, "Gut-islet endocrinology—some evolutionary aspects," Investigative and Cell Pathology, vol. 3, no. 1, pp. 21–35, 1980.
[51] S. Bavamian, P. Klee, A. Britan et al., "Islet-cell-to-cell communication as basis for normal insulin secretion," Diabetes, Obesity and Metabolism, vol. 9, supplement 2, pp. 118–132, 2007.
[52] D. Caton, A. Calabrese, C. Mas, V. Serre-Beinier, A. Wonkam, and P. Meda, "β-cells: a further dimension in the stimulus-secretion coupling of glucose-induced insulin release," Diabetes and Metabolism, vol. 28, no. 6, pp. 3–5, 2002.
[53] R. Jain and E. Lammert, "Cell-cell interactions in the endocrine pancreas," Diabetes, Obesity and Metabolism, vol. 11, supplement 4, pp. 159–167, 2009.
[54] P. Meda, "The role of gap junction membrane channels in secretion and hormonal action," Journal of Bioenergetics and Biomembranes, vol. 28, no. 4, pp. 369–377, 1996.
[55] R. N. Nlend, L. Michon, S. Bavamian et al., "Connexin36 and pancreatic β-cell functions," Archives of Physiology and Biochemistry, vol. 112, no. 2, pp. 74–81, 2006.
[56] P. Meda and D. Bosco, "Communication of islet cells: molecules, mechanisms, functions," in Molecular Basis of Endocrine Pancreas Development and Functions, J. F. Habener and M. Hussein, Eds., pp. 138–159, Springer, Berlin, Germany, 2001.
[57] I. Potolicchio, V. Cigliola, S. Velazquez-Garcia et al., "Connexin-dependent signaling in neuro-hormonal systems," Biochimica et Biophysica Acta, vol. 1818, no. 8, pp. 1919–1936, 2012.
[58] M. Brissova and A. C. Powers, "Architecture of pancreatic islets," in Pancreatic Beta Cell in Health and Disease, S. Seino and G. I. Bell, Eds., pp. 3–11, Springer, Berlin, Germany, 2008.
[59] R. K. P. Benninger, M. Zhang, W. S. Head, L. S. Satin, and D. W. Piston, "Gap junction coupling and calcium waves in the pancreatic islet," Biophysical Journal, vol. 95, no. 11, pp. 5048–5061, 2008.
[60] E. Gylfe, E. Grapengiesser, Y. J. Liu, S. Dryselius, A. Tengholm, and M. Eberhardsson, "Generation of glucose-dependent slow oscillations of cytoplasmic Ca²⁺ in individual pancreatic β-cells," Diabetes and Metabolism, vol. 24, no. 1, pp. 25–29, 1998.
[61] B. Hellman, E. Gylfe, E. Grapengiesser, P. E. Lund, and A. Berts, "Cytoplasmic Ca²⁺ oscillations in pancreatic β-cells," Biochimica et Biophysica Acta, vol. 1113, no. 3–4, pp. 295–305, 1992.
[62] M. A. Ravier, M. Gündenagel, A. Charollais et al., "Loss of connexin36 channels alters β-cell coupling, islet synchronization of glucose-induced Ca²⁺ and insulin oscillations, and basal insulin release," Diabetics, vol. 54, no. 6, pp. 1798–1807, 2005.
[63] B. Hellman, A. Salehi, E. Gylfe, H. Dansk, and E. Grapengiesser, "Glucose generates coincident insulin and somatostatin pulses and asynchronous glucagon pulses from human pancreatic islets," Endocrinology, vol. 150, no. 11, pp. 5334–5340, 2009.
[64] P. O. Berggren, P. Rorsman, S. Efendic et al., "Mechanism of action of entero-insular hormones, islet peptides and neural input on the insulin secretory process," in Nutrient Regulation of Insulin Secretion, P. R. Flatt, Ed., pp. 289–319, Portland Press, London, UK, 1992.
[65] D. G. Pipeleers, F. C. Schuit, and P. A. in’t Veld, "Interplay of nutrients and hormones in the regulation of insulin release," Endocrinology, vol. 117, no. 3, pp. 824–833, 1985.
[66] J. I. Stagner, "Pulsatile secretion from the endocrine pancreas: metabolic, hormonal and neural modulation," in The Endocrine Pancreas, E. Samole, Ed., pp. 283–302, Raven, New York, NY, USA, 1991.
[67] C. B. Wollheim and G. W. Sharp, "Regulation of insulin release by calcium," Physiological Reviews, vol. 61, no. 4, pp. 914–973, 1981.
[68] C. J. Goodner, D. J. Koerker, J. I. Stagner, and E. Samols, "In vitro pancreatic hormonal pulses are less regular and more frequent than in vivo," American Journal of Physiology, vol. 260, no. 3, pp. 4424–4429, 1991.
[69] E. Samols and J. I. Stagner, "Intra-islet and islet-acinar portal systems and their significance," in The Endocrine Pancreas, E. Samols, Ed., pp. 93–124, Raven Press, New York, NY, USA, 1991.
[70] V. Marks, E. Samols, and J. Stagner, “Intra-islet interactions,” in *Nutrient Regulation of Insulin Secretion*, P. R. Flatt, Ed., pp. 41–57, Portland Press, London, UK, 1992.

[71] D. Pipeleers, “Islet cell interactions with pancreatic B-cells,” *Experientia*, vol. 40, no. 10, pp. 1114–1126, 1984.

[72] B. S. Chertov, N. G. Baranetsky, and W. I. Sivitz, “Cellular mechanisms of insulin release. Effects of retinoids on rat islet cell-to-cell adhesion, reaggregation, and insulin release,” *Diabetes*, vol. 32, no. 6, pp. 568–574, 1983.

[73] P. A. Halban, C. B. Wollheim, B. Blondel, P. Meda, E. N. Niesor, and D. H. Mintz, “The possible importance of contact between pancreatic islet cells for the control of insulin release,” *Endocrinology*, vol. 111, no. 1, pp. 86–94, 1982.

[74] E. Maes and D. Pipeleers, “Effects of glucose and 3',5'-cyclic adenosine monophosphate upon reaggregation of single pancreatic B-cells,” *Endocrinology*, vol. 114, no. 6, pp. 2205–2209, 1984.

[75] A. Lernmark, “The preparation of, and studies on, free cell suspensions from mouse pancreatic islets,” *Diabetologia*, vol. 10, no. 5, pp. 431–438, 1974.

[76] D. G. Pipeleers, “Heterogeneity in pancreatic β-cell population,” *Diabetes*, vol. 41, no. 7, pp. 777–781, 1992.

[77] D. Salomon and P. Meda, “Heterogeneity and contact-dependent regulation of hormone secretion by individual B cells,” *Experimental Cell Research*, vol. 162, no. 2, pp. 507–520, 1986.

[78] D. Bosco, L. Orci, and P. Meda, “Homologous but not heterologous contact increases the insulin secretion of individual pancreatic B-cells,” *Experimental Cell Research*, vol. 184, no. 1, pp. 72–80, 1989.

[79] K. Kawai, E. Ipp, and L. Orci, “Circulating somatostatin acts on the islets of Langerhans by way of a somatostatin-poor compartment,” *Science*, vol. 218, no. 4571, pp. 477–478, 1982.

[80] R. N. Kulkarni, J. C. Brüning, J. N. Winnay, C. Postic, M. A. Magnuson, and C. R. Kahn, “Tissue-specific knockout of the insulin receptor in pancreatic β-cells creates an insulin secretory defect similar to that in type 2 diabetes,” *Cell*, vol. 96, no. 3, pp. 329–339, 1999.

[81] P. Rorsman and G. Trube, “Calcium and delayed potassium currents in mouse pancreatic β-cells under voltage-clamp conditions,” *The Journal of Physiology*, vol. 374, pp. 531–550, 1986.

[82] R. Rodríguez-Díaz, M. H. Abdulreda, A. L. Formoso et al., “Innervation patterns of autonomic axons in the human endocrine pancreas,” *Cell Metabolism*, vol. 14, pp. 45–54, 2011.

[83] R. Rodríguez-Díaz, R. Dando, M. C. Jacques-Silva et al., “Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans,” *Nature Medicine*, vol. 17, pp. 888–892, 2011.

[84] L. C. Falke, K. D. Gillis, D. M. Pressel, and S.Misler, “‘Perforated patch recording’ allows long-term monitoring of metabolite-induced electrical activity and voltage-dependent Ca2+ currents in pancreatic islet B cells,” *FEBS Letters*, vol. 251, no. 1-2, pp. 167–172, 1989.

[85] H. P. Meissner, “Electrophysiological evidence for coupling between β cells of pancreatic islets,” *Nature*, vol. 262, no. 5568, pp. 502–504, 1976.

[86] G. T. Eddlestone, A. Goncalves, J. A. Bangham, and E. Rojas, “Electrical coupling between cells in islets of Langerhans from mouse,” *Journal of Membrane Biology*, vol. 77, no. 1, pp. 1–14, 1984.

[87] P. Meda, I. Atwater, and A. Goncalves, “The topography of electrical synchrony among β-cells in the mouse islet of Langerhans,” *Quarterly Journal of Experimental Physiology*, vol. 69, no. 4, pp. 719–735, 1984.

[88] M. Valdeolmillos, A. Nadal, B. Soria, and J. García-Sancho, “Fluorescence digital image analysis of glucose-induced [Ca2+]i oscillations in mouse pancreatic islets of Langerhans,” *Diabetes*, vol. 42, no. 8, pp. 1210–1214, 1993.

[89] M. Valdeolmillos, R. M. Santos, D. Contreras, B. Soria, and L. M. Rosario, “Glucose-induced oscillations of intracellular Ca2+ concentration resembling bursting electrical activity in single mouse islets of Langerhans,” *FEBS Letters*, vol. 259, no. 1, pp. 19–23, 1989.

[90] E. Pérez-Armendariz, I. Atwater, and E. Rojas, “Glucose-induced oscillatory changes in extracellular ionized potassium concentration in mouse islets of Langerhans,” *Biophysical Journal*, vol. 48, pp. 741–749, 1985.

[91] D. Bleich, S. Chen, J. L. Gu, and J. L. Nadler, “The role of 12-lipoxygenase in pancreatic cells,” *International Journal of Molecular Medicine*, vol. 1, no. 1, pp. 265–272, 1998.

[92] M. L. McDaniel, J. A. Corbett, G. Kwon, and J. R. Hill, “A role for nitric oxide and other inflammatory mediators in cytokine-induced pancreatic β-cell dysfunction and destruction,” *Advances in Experimental Medicine and Biology*, vol. 426, pp. 313–319, 1997.

[93] D. L. Eizirik, M. Flodström, A. E. Karlsen, and N. Welsh, “The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells,” *Diabetologia*, vol. 39, no. 8, pp. 875–890, 1996.

[94] J. M. Argiles, J. Lopez-Soriano, M. A. Ortiz, J. M. Pou, and F. J. Lopez-Soriano, “Interleukin-1 and β-cell function: more than one second messenger?”, *Endocrine Reviews*, vol. 13, no. 3, pp. 515–524, 1992.

[95] R. O. Hynes, “Integrins: bidirectional, allosteric signaling machines,” *Cell*, vol. 110, no. 6, pp. 673–687, 2002.

[96] F. G. Giancotti and E. Ruoslahti, “Integrin signaling,” *Science*, vol. 285, no. 5430, pp. 1028–1032, 1999.

[97] A. M. Belkin and M. A. Stepp, “Integrins as receptors for laminins,” *Microscopy Research and Technique*, vol. 51, pp. 280–301, 2000.

[98] C. K. Miranti and J. S. Brugge, “Sensing the environment: a historical perspective on integrin signal transduction,” *Nature Cell Biology*, vol. 4, no. 4, pp. E83–E90, 2002.

[99] M. A. Schwartz and M. H. Ginsberg, “Networks and crosstalk: integrin signalling spreads,” *Nature Cell Biology*, vol. 4, no. 4, pp. E65–E68, 2002.

[100] J. T. Parsons, “Focal adhesion kinase: the first ten years,” *Journal of Cell Science*, vol. 116, no. 8, pp. 1409–1416, 2003.

[101] M. A. Schwartz, “Integrin signaling revisited,” *Trends in Cell Biology*, vol. 11, no. 12, pp. 466–470, 2001.

[102] A. K. Howe, A. E. Aplin, and R. L. Juliano, “Anchorage-dependent ERK signaling—mechanisms and consequences,” *Current Opinion in Genetics and Development*, vol. 12, no. 1, pp. 30–35, 2002.

[103] F. Levine, G. M. Beattie, and A. Hayek, “Differential integrin expression facilitates isolation of human fetal pancreatic epithelial cells,” *Cell Transplantation*, vol. 3, no. 4, pp. 307–313, 1994.

[104] R. N. Wang, S. Paraskevas, and L. Rosenberg, “Characterization of integrin expression in islets isolated from hamster, canine, porcine, and human pancreas,” *Journal of Histochemistry and Cytochemistry*, vol. 47, no. 4, pp. 499–506, 1999.
[200] A. K. Perl, U. Dahl, P. Wilgenbus, H. Cremer, H. Semb, and G. Christofori, "Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic β tumor cells," *Nature Medicine*, vol. 5, no. 3, pp. 286–291, 1999.

[201] M. J. Luther, E. Davies, D. Muller et al., "Cell-to-cell contact influences proliferative marker expression and apoptosis in MIN6 cells grown in islet-like structures," *American Journal of Physiology*, vol. 288, no. 3, pp. E502–E509, 2005.

[202] L. L. Field, "Genetic linkage and association studies of type I diabetes: challenges and rewards," *Diabetologia*, vol. 45, no. 1, pp. 21–35, 2002.

[203] M. Sleeter, A. S. Diamond, and R. G. Gill, "Islet allograft rejection by contact-dependent CD8⁺ T cells: perforin and FasL play alternate but obligatory roles," *American Journal of Transplantation*, vol. 7, no. 8, pp. 1927–1933, 2007.

[204] K. L. Cepek, S. K. Shaw, C. M. Parker et al., "Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the α(E)β7 integrin," *Nature*, vol. 372, no. 6502, pp. 190–193, 1994.

[205] Y. Feng, D. Wang, R. Yuan, C. M. Parker, D. L. Farber, and G. A. Hadley, "CD103 expression is required for destruction of pancreatic islet allografts by CD8⁺ T cells," *Journal of Experimental Medicine*, vol. 196, no. 7, pp. 877–886, 2002.

[206] M. Koval, "Claudin heterogeneity and control of lung tight junctions," *Annual Review of Physiology*. In press.

[207] M. Cereijido and J. Anderon, Eds., *Tight Junctions*, vol. 61, no. 2, pp. 225–246, 1970.

[208] Trends in Cell Biology

[209] M. Koval, "Claudin heterogeneity and control of lung tight junctions," *Annual Review of Physiology*. In press.

[210] E. Charpentier, J. Cancela, and P. Meda, "Beta cells preferentially exchange cationic molecules via connexin 36 gap junction channels," *Diabetologia*, vol. 50, no. 11, pp. 2332–2341, 2007.

[211] E. Kohen, C. Kohen, and B. Thorrell, "Intercellular communication in pancreatic islet monolayer cultures: a microfluorometric study," *Science*, vol. 204, no. 4395, pp. 862–865, 1979.

[212] D. Mears, N. F. Sheppard Jr., I. Atwater, and E. Rojas, "Magnitude and modulation of pancreatic β-cell gap junction electrical conductance in situ," *Journal of Membrane Biology*, vol. 146, no. 2, pp. 163–176, 1995.

[213] P. Meda, I. Atwater, and A. Goncalves, "The topography of electrical synchrony among β-cells in the mouse islet of Langerhans," *Quarterly Journal of Experimental Physiology*, vol. 69, no. 4, pp. 719–735, 1984.

[214] H. P. Meissner, "Electrophysiological evidence for coupling between β-cells of pancreatic islets," *Nature*, vol. 262, no. 5568, pp. 502–504, 1976.

[215] S. Speier, A. Gjinovci, A. Charollais, P. Meda, and M. Rupnik, "Cx36-mediated coupling reduces β-cell heterogeneity, confines the stimulating glucose concentration range, and affects insulin release kinetics," *Diabetes*, vol. 56, no. 4, pp. 1078–1086, 2007.

[216] F. C. Jonkers, J. C. Jonas, P. Gilon, and J. C. Henquin, "Influence of cell number on the characteristics and synchrony of Ca²⁺ oscillations in clusters of mouse pancreatic islets," *The Journal of Physiology*, vol. 520, no. 3, pp. 839–849, 1999.

[217] W. S. Head, M. L. Orseth, C. S. Nunemaker et al., "Connexin-36 gap junctions regulate OA and glucose tolerance in the conscious mouse," *Diabetes*, vol. 61, pp. 1700–1707, 2012.

[218] V. Serre-Beinier, D. Bosco, L. Zumianiello et al., "Cx36 makes channels coupling human pancreatic β-cells, and correlates with insulin expression," *Human Molecular Genetics*, vol. 18, no. 3, pp. 428–439, 2009.

[219] P. Meda, N. F. Sheppard Jr., I. Atwater, and E. Rojas, "Magnitude and modulation of pancreatic β-cell gap junction electrical conductance in situ," *Journal of Membrane Biology*, vol. 146, no. 2, pp. 163–176, 1995.

[220] E. Charpentier, J. Cancela, and P. Meda, "Beta cells preferentially exchange cationic molecules via connexin 36 gap junction channels," *Diabetologia*, vol. 50, no. 11, pp. 2332–2341, 2007.

[221] E. Kohen, C. Kohen, and B. Thorrell, "Intercellular communication in pancreatic islet monolayer cultures: a microfluorometric study," *Science*, vol. 204, no. 4395, pp. 862–865, 1979.

[222] P. Meda, M. Amherdt, A. Perrelet, and L. Orci, "Metabolic coupling between cultured pancreatic B-cells," *Experimental Cell Research*, vol. 133, no. 2, pp. 421–430, 1981.

[223] P. Meda, R. L. Michaels, and P. A. Halban, "In vivo modulation of gap junctions and dye coupling between B-cells of the intact pancreatic islet," *Diabetes*, vol. 32, no. 9, pp. 858–868, 1983.

[224] A. Calabrese, M. Zhang, V. Serre-Beinier et al., "Connexin-36 controls synchronization of Ca²⁺ oscillations and insulin secretion in MIN6 cells," *Diabetes*, vol. 52, no. 2, pp. 417–424, 2003.

[225] F. C. Jonkers, J. C. Jonas, P. Gilon, and J. C. Henquin, "Influence of cell number on the characteristics and synchrony of Ca²⁺ oscillations in clusters of mouse pancreatic islets," *The Journal of Physiology*, vol. 520, no. 3, pp. 839–849, 1999.

[226] W. S. Head, M. L. Orseth, C. S. Nunemaker et al., "Connexin-36 gap junctions regulate OA and glucose tolerance in the conscious mouse," *Diabetes*, vol. 61, pp. 1700–1707, 2012.

[227] V. Serre-Beinier, D. Bosco, L. Zumianiello et al., "Cx36 makes channels coupling human pancreatic β-cells, and correlates with insulin expression," *Human Molecular Genetics*, vol. 18, no. 3, pp. 428–439, 2009.

[228] P. Klee, F. Allaghat, H. Pontes et al., "Connexins protect mouse pancreatic β-cells against apoptosis," *The Journal of Clinical Investigation*, vol. 121, pp. 4870–4879, 2011.

[229] J. Philippe, E. Giordano, A. Gjinovci, and P. Meda, "Cyclic adenosine monophosphate prevents the glucocorticoid-mediated inhibition of insulin gene expression in rodent islet
cells,” *The Journal of Clinical Investigation*, vol. 90, no. 6, pp. 2228–2233, 1992.

[237] F. C. Schuit, P. A. in't Veld, and D. G. Pipeleers, “Glucose stimulates proinsulin biosynthesis by a dose-dependent recruitment of pancreatic beta cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 85, no. 11, pp. 3865–3869, 1988.

[238] P. Meda, P. Halban, and A. Perrelet, “Gap junction development is correlated with insulin content in the pancreatic B cell,” *Science*, vol. 209, no. 4460, pp. 1026–1028, 1980.

[239] C. P. F. Carvalho, H. C. L. Barbosa, A. Britan et al., “Beta cell coupling and connexin expression change during the functional maturation of rat pancreatic islets,” *Diabetologia*, vol. 53, no. 7, pp. 1428–1437, 2010.

[240] C. P. Carvalho, R. B. Oliveira, A. Britan, J. C. Santos-Silva et al., “Impaired β-cell-β-cell coupling mediated by Cx36 gap junctions in prediabetic mice,” *American Journal of Physiology*, vol. 303, pp. E144–E151, 2012.

[241] R. N. Nlend, A. Aït-Lounis, F. Allagnat et al., “Cx36 is a target of Betα2/NeuroD1, which associates with prenatal differentiation of insulin-producing β cells,” *Journal of Membrane Biology*, vol. 245, pp. 263–273, 2012.

[242] D. Bosco, P. Meda, B. Thorens, and W. J. Malaisse, “Heterogeneous secretion of individual B cells in response to D-glucose and to nonglucidic nutrient secretagogues,” *American Journal of Physiology*, vol. 268, no. 3, pp. C611–C618, 1995.

[243] D. Bosco and P. Meda, “Actively synthesizing β-cells secrete preferentially after glucose stimulation,” *Endocrinology*, vol. 129, no. 6, pp. 3157–3166, 1991.

[244] F. C. Jonkers and J. C. Henquin, “Measurements of cytoplasmic Ca2+ in islet cell clusters show that glucose rapidly recruits β-cells and gradually increases the individual cell response,” *Diabetes*, vol. 50, no. 3, pp. 540–550, 2001.

[245] D. Pipeleers, P. in’t Veld, E. Maes, and M. van De Winkel, “Glucose-induced insulin release depends on functional cooperation between islet cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 79, no. 23 I, pp. 7322–7325, 1982.

[246] P. Meda, D. Bosco, M. Chansen et al., “β-Cells secretory changes during uncoupling of rat insulin-producing cells,” *The Journal of Clinical Investigation*, vol. 86, no. 3, pp. 759–768, 1990.

[247] A. Charollais, A. Gjinovci, J. Huarte et al., “Functional communication of pancreatic β cell contributes to the control of insulin secretion and glucose tolerance,” *The Journal of Clinical Investigation*, vol. 106, no. 2, pp. 235–243, 2000.

[248] R. K. Benninger, W. S. Head, M. Zhang, L. S. Satin, and D. W. Piston, “Gap junctions and other mechanisms of cell-cell communication regulate basal insulin secretion in the pancreatic islet,” *The Journal of Physiology*, vol. 589, pp. 5453–5466, 2011.

[249] P. Meda, “The in vivo β-to-β cell chat room: connexin connections matter,” *Diabetes*, vol. 61, pp. 1656–1658, 2012.

[250] R. L. Michaels, R. L. Sorenson, J. A. Parsons, and J. D. Sheridan, “Prolactin enhances cell-to-cell communication among β-cells in pancreatic islets,” *Diabetes*, vol. 36, no. 10, pp. 1098–1103, 1987.

[251] P. Klee, S. Lamprianou, A. Charollais et al., “Connexin implication in the control of the murine beta-cell mass,” *Pediatric Research*, vol. 70, no. 2, pp. 142–147, 2011.

[252] R. K. P. Benninger, M. S. Remedi, W. S. Head, A. Ustione, D. W. Piston, and C. G. Nichols, “Defects in beta cell Ca2+ signalling, glucose metabolism and insulin secretion in a murine model of KATP channel-induced neonatal diabetes mellitus,” *Diabetologia*, vol. 54, no. 5, pp. 1087–1097, 2011.

[253] Y. Stefan, P. Meda, M. Neufeld, and L. Orci, “Stimulation of insulin secretion reveals heterogeneity of pancreatic B cells in vivo,” *The Journal of Clinical Investigation*, vol. 80, no. 1, pp. 175–183, 1987.

[254] H. Heimberg, A. de Vos, A. Vandercammen, E. van Schaftingen, D. Pipeleers, and F. Schuit, “Heterogeneity in glucose sensitivity among pancreatic β-cells is correlated to differences in glucose phosphorylation rather than glucose transport,” *The EMBO Journal*, vol. 12, no. 7, pp. 2873–2879, 1993.

[255] J. A. Haelfliger, D. Martin, D. Favre et al., “Reduction of connexin36 content by ICER-1 contributes to insulin-secreting cells apoptosis induced by oxidized LDL particles,” *PLoS One*. In press.

[256] F. Allagnat, P. Klee, M. Peyrou et al., “The gap junctional protein connexin36 (Cx36) protects pancreatic beta cells against cytotoxic attacks: a possible role in cytokine-mediated beta cell death,” *Diabetologia*, vol. 50, p. 545, 2007.

[257] B. Kutlu, A. K. Cardozo, M. I. Darville et al., “Discovery of gene networks regulating cytokine-induced dysfunction and apoptosis in insulin-producing INS-1 cells,” *Diabetes*, vol. 52, no. 11, pp. 2701–2719, 2003.

[258] L. Orci, F. Malaisse-Lagae, and M. Ravazzola, “A morphological basis for intercellular communication between α and β cells in the endocrine pancreas,” *The Journal of Clinical Investigation*, vol. 56, no. 4, pp. 1066–1070, 1975.

[259] P. Meda, E. Kohen, and C. Kohen, “Direct communication of homologous and heterologous endocrine islet cells in culture,” *Journal of Cell Biology*, vol. 92, no. 1, pp. 221–226, 1982.

[260] A. Ito, N. Ishiyanagi, Y. Ikeda et al., “Adhesion molecule CADM1 contributes to gap junctional communication among pan-creatic islet α-cells and prevents their excessive secretion of glucagon,” *Ilets*, vol. 4, pp. 49–55, 2012.

[261] T. Kanno, S. O. Göpel, P. Rorsman, and M. Wikn, “Cellular function in multicellular system for hormone-secretion: electrophysiological aspect of studies on α-, β- and δ-cells of the pancreatic islet,” *Neuroscience Research*, vol. 42, no. 2, pp. 79–90, 2002.

[262] I. Quesada, E. Fuentes, E. Andreu, P. Meda, A. Nadal, and B. Soria, “On-line analysis of gap junctions reveals more efficient electrical than dye coupling between islet cells,” *American Journal of Physiology*, vol. 284, no. 5, pp. E980–E987, 2003.

[263] A. Nadal, I. Quesada, and B. Soria, “Homologous and heterologous asynchronicity between is α-, β- and δ-cells within intact islets of Langerhans in the mouse,” *The Journal of Physiology*, vol. 517, no. 1, pp. 85–93, 1999.

[264] A. Nadal, I. Quesada, and B. Soria, “Homologous and heterologous asynchronicity between identified α-, β- and δ-cells within intact islets of Langerhans in the mouse,” *The Journal of Physiology*, vol. 517, no. 1, pp. 85–93, 1999.

[265] N. Belluardo, A. Trovato-Salinaro, G. Mudò, Y. L. Hurd, and D. F. Condorelli, “Structure, chromosomal localization, and brain expression of human Cx36 gene,” *Journal of Neuroscience Research*, vol. 57, pp. 740–752, 1999.

[266] Y. Mori, S. Otobe, C. Dina et al., “Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate loci on 7p and 11p.” *Diabetes*, vol. 51, no. 4, pp. 1247–1255, 2002.
[267] R. Hamelin, F. Allagnat, J. A. Haefliger, and P. Meda, "Connexins, diabetes and the metabolic syndrome," Current Protein and Peptide Science, vol. 10, no. 1, pp. 18–29, 2009.

[268] F. Allagnat, D. Martin, D. F. Condorelli, G. Waerber, and J. A. Haefliger, "Glucose represses connexin36 in insulin-secreting cells," Journal of Cell Science, vol. 118, no. 22, pp. 5335–5344, 2005.

[269] F. Allagnat, F. Alonso, D. Martin, A. Abderrahmani, G. Waerber, and J. A. Haefliger, "ICER-1γ overexpression drives palmitate-mediated connexin36 down-regulation in insulin-secreting cells," Journal of Biological Chemistry, vol. 283, no. 9, pp. 5226–5234, 2008.

[270] J. A. Haefliger, D. Martin, D. Favre et al., "Reduction of Connexin36 content by ICER-1 contributes to insulin-secreting cells apoptosis induced by oxidized LDL particles".

[271] C. Mas, N. Taske, S. Deutsch et al., "Association of the connexin36 gene with juvenile myoclonic epilepsy," Journal of Medical Genetics, vol. 41, no. 7, pp. e93–e98, 2004.

[272] A. Hempelmann, A. Heils, and T. Sander, "Confirmatory evidence for an association of the connexin-36 gene with juvenile myoclonic epilepsy," Epilepsy Research, vol. 71, no. 2-3, pp. 223–228, 2006.

[273] J. Rasschaert, D. Liu, B. Kutlu et al., "Global profiling of double stranded RNA- and IFN-γ-induced genes in rat pancreatic beta cells," Diabetologia, vol. 46, no. 12, pp. 1641–1657, 2003.

[274] S. Bavamian, H. Pontes, J. Cancela et al., "The intercellular synchronization of Ca2+ oscillations evaluates Cx36-dependent coupling," PLoS ONE, vol. 7, Article ID e41535, 2012.

[275] M. Oyamada, Y. Oyamada, T. Kaneko, and T. Takamatsu, "Regulation of gap junction protein (connexin) genes and function in differentiating ES cells," Methods in Molecular Biology, vol. 185, pp. 63–69, 2002.

[276] P. Wörsdörfer, S. Maxeiner, C. Markopoulos et al., "Connexin expression and functional analysis of gap junctional communication in mouse embryonic stem cells," Stem Cells, vol. 26, pp. 431–439, 2008.

[277] D. R. Bhandari, K. W. Seo, B. Sun et al., "The simplest method for in vitro β-cell production from human adult stem cells," Differentiation, vol. 82, pp. 144–152, 2011.

[278] E. M. Hartfield, F. Rinaldi, C. P. Glover, L. F. Wong, M. A. Caldwell, and J. B. Uney, "Connexin 36 expression regulates neuronal differentiation from neural progenitor cells," PLoS ONE, vol. 6, no. 3, Article ID e14746, 2011.